Health Canada has officially approved SCENESSE® (afamelanotide), a revolutionary treatment for erythropoietic protoporphyria (EPP), offering new hope and brighter days ahead for individuals battling this rare and debilitating light-sensitive genetic disorder
Merck KGaA, Darmstadt, Germany, joins forces with Versant Ventures to launch Saturnus Bio, an exciting new biotech venture committed to revolutionizing treatments for rare genetic cardiomyopathies and expanding the frontier of groundbreaking therapies
India's general doctors are sounding the alarm on a critical gap: the urgent need for rare disease training. Experts warn that delayed diagnoses are still standing in the way of effective patient care. By ramping up awareness and education, we have the chance to transform outcomes for millions nationwide
Health Canada has broadened the approval of Evkeeza® (evinacumab) to treat homozygous familial hypercholesterolemia (HoFH) in children as young as 6 months, offering exciting new hope for early and powerful treatment
Exciting news from Japan! The Ministry of Health, Labour and Welfare (MHLW) has officially approved Sarepta Therapeutics' groundbreaking gene therapy for Duchenne muscular dystrophy (DMD). This pivotal decision opens up new horizons for patients in Japan battling this challenging condition, offering hope and enhanced treatment options like never before.
UK health officials reported a case of clade 1b mpox with no travel history or connections to previous infections. This unexpected occurrence raises concerns about potential community transmission as experts urge vigilance and continued monitoring.
